Monte Rosa Therapeutics, Inc. financial data

Symbol
GLUE on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
321 Harrison Avenue, Suite 900, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 586 % -50%
Debt-to-equity 57.5 % +119%
Return On Equity -70.4 % -43.2%
Return On Assets -44.7 % -14.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.4M shares
Common Stock, Shares, Outstanding 61.3M shares +23.7%
Entity Public Float 234M USD -22.6%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 71.2M shares +44.1%
Weighted Average Number of Shares Outstanding, Diluted 71.2M shares +44.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 111M USD +8.31%
General and Administrative Expense 34.7M USD +14.4%
Operating Income (Loss) -139M USD -5.36%
Nonoperating Income (Expense) 9.49M USD +31.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -130M USD +14.1%
Income Tax Expense (Benefit) 483K USD +154%
Net Income (Loss) Attributable to Parent -130M USD -4.07%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 109M USD +131%
Accounts Receivable, after Allowance for Credit Loss, Current 9M USD
Assets, Current 278M USD +33.5%
Property, Plant and Equipment, Net 33.3M USD -5.9%
Operating Lease, Right-of-Use Asset 27.9M USD -8.12%
Other Assets, Noncurrent 209K USD -28.2%
Assets 344M USD +23.5%
Accounts Payable, Current 6.47M USD +21.9%
Employee-related Liabilities, Current 5.14M USD +15.3%
Liabilities, Current 42.3M USD +122%
Operating Lease, Liability, Noncurrent 40.9M USD -7.85%
Liabilities 119M USD +83.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.67M USD -62.8%
Retained Earnings (Accumulated Deficit) -428M USD -43.8%
Stockholders' Equity Attributable to Parent 225M USD +5.16%
Liabilities and Equity 344M USD +23.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.2M USD -63.1%
Net Cash Provided by (Used in) Financing Activities 246K USD
Net Cash Provided by (Used in) Investing Activities 9.85M USD -51.5%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 61.3M shares +23.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -28.1M USD -817%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 114M USD +121%
Deferred Tax Assets, Valuation Allowance 54.5M USD +64.6%
Deferred Tax Assets, Gross 66.6M USD +43.8%
Operating Lease, Liability 5.4M USD
Depreciation 7.64M USD +64.4%
Payments to Acquire Property, Plant, and Equipment 1.38M USD -84.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -131M USD -5.58%
Property, Plant and Equipment, Gross 49.5M USD +12.6%
Operating Lease, Liability, Current 3.47M USD +30.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 41.9M USD +60.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.48M USD +100%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 6.4M USD
Amortization of Intangible Assets 800K USD 0%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 6.2M USD
Deferred Tax Assets, Net of Valuation Allowance 12.2M USD -8.16%
Share-based Payment Arrangement, Expense 4.87M USD +22.6%
Operating Leases, Future Minimum Payments, Due in Three Years 6.6M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%